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Muscle relaxants are frequently used to facilitate endo-
tracheal intubation during the induction of anesthesia
[1,2]. However, the administration of short-acting
depolarizing muscle relaxants is associated with post-
operative myalgias, malignant hyperthermia, hyper-
kalemia and increased intracranial or intraocular
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The aim of this study was to compare the effects of fentanyl or dexmedetomidine when used in
combination with propofol and lidocaine for tracheal intubation without using muscle relaxants.
Sixty patients with American Society of Anesthesiologists stage I risk were randomized to receive
1 μg/kg dexmedetomidine (Group D, n = 30) or 2 μg/kg fentanyl (Group F, n = 30), both in combi-
nation with 1.5 mg/kg lidocaine and 3 mg/kg propofol. The requirement for intubation was
determined based on mask ventilation capability, jaw motility, position of the vocal cords and the
patient’s response to intubation and inflation of the endotracheal tube cuff. Systolic arterial pres-
sure, mean arterial pressure, heart rate and peripheral oxygen saturation values were also
recorded. Rate pressure products were calculated. Jaw relaxation, position of the vocal cords and
patient’s response to intubation and inflation of the endotracheal tube cuff were significantly bet-
ter in Group D than in Group F (p < 0.05). The intubation conditions were significantly more satis-
factory in Group D than in Group F (p = 0.01). Heart rate was significantly lower in Group D than
in Group F after the administration of the study drugs and intubation (p < 0.05). Mean arterial
pressure was significantly lower in Group F than in Group D after propofol injection and at 3 and
5 minutes after intubation (p < 0.05). After intubation, the rate pressure product values were sig-
nificantly lower in Group D than in Group F (p < 0.05). We conclude that endotracheal intubation
was better with the dexmedetomidine–lidocaine–propofol combination than with the
fentanyl–lidocaine–propofol combination. However, side effects such as bradycardia should be
considered when using dexmedetomidine.
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pressure. The use of non-depolarizing muscle relax-
ants may cause prolonged neuromuscular blockade,
potentiate histamine release, increase the risk of side
effects associated with anticholinesterase-mediated
reversal of these agents, and prevent rapid reversal of
neuromuscular blockade in the event of an unex-
pected difficult intubation [1–6]. When the use of
muscle relaxants is undesirable or contraindicated,
the administration of correct induction agents to pro-
vide good intubating conditions without using mus-
cle relaxants is an important consideration [1–5].
Dexmedetomidine is a highly selective α2 adreno-
ceptor agonist with analgesic and sedative effects, but
it does not cause respiratory depression [7–9]. It is
commonly used in the intensive care unit and is a well
tolerated and acceptable sedative agent [7–9]. In com-
bination with propofol, dexmedetomidine has been
demonstrated to assist in extubation, fiberoptic intu-
bation, awake blind nasotracheal intubation and laryn-
geal mask airway placement [7–14]. Although propofol
with fentanyl, remifentanil alfentanil and lidocaine
has successfully been used for endotracheal intubation
without muscle relaxants [1–3,15,16], there is no infor-
mation on dexmedetomidine in combination with pro-
pofol for laryngoscopic endotracheal intubation in the
absence of muscle relaxants. Therefore, the aim of this
study was to investigate the efficacy of dexmedeto-
midine-lidocaine-propofol compared with fentanyl-
lidocaine-propofol for laryngoscopy and endotracheal
intubation in the absence of muscle relaxants.
METHODS
After approval of the hospital ethics committee and
having informed consent from the patients, a total of 60
patients were enrolled in this study. All patients were
aged between 18–59 years, with American Society of
Anesthesiologists stage I risk, and with no history of
drug or alcohol abuse or cardiovascular and cere-
brovascular diseases. The patients were hospitalized
for elective surgery under general anesthesia and had
difficult intubations. All patients were all Mallampati
Class I and had a body mass index of < 30 kg/m2. The
patients were randomized into two equal groups using
a random samples table.
Thirty minutes before induction, all patients 
were premedicated with an intramuscular injection
of 0.07 mg/kg midazolam. In the operation room, a
20-G cannula was inserted for intravenous access,
and 5–7 mL/kg of Ringer’s lactate solution was
administered.
The baseline arterial blood pressure, peripheral
oxygen saturation, electrocardiogram and end-tidal
CO2 measurements were obtained for all patients using
standard monitoring equipment. Preoxygenation was
performed for 3 minutes with 5L/min of 100% oxygen.
After preoxygenation, Group D received 1 μg/kg
dexmedetomidine (100 μg/mL; Precedex, Hospira
Inc., Lake Forest, IL, USA) diluted to a total volume
of 10 mL and infused within 10 minutes using a cali-
brated electronic infusion pump (Braun Infusomat,
Braun, Melsungen Germany) (Figure 1). Then, 5 mL
of 0.9% saline was administered within 30 seconds.
Group F received 10 mL of 0.9% saline infused within
10 minutes using a calibrated electronic infusion pump
followed by 2 μg/kg fentanyl (50 μg/mL; Fentanyl
Citrate, Hospira Inc.), which was diluted to a total
volume of 5 mL and administered within 30 seconds.
Immediately after administration of medications, all
patients were given 1.5 mg/kg lidocaine, not to exceed
a total of 100 mg per patient, followed by 3 mg/kg
propofol over 30 seconds. After loss of consciousness,
mask ventilation was initiated. Mask ventilation was
Dexmedetomidine infusion Saline 0.9% Lidocaine
Lidocaine
Propofol
PropofolSaline 0.9% infusion
PreoxygenationPremedication
30 min 3 min 10 min
60 sec
Mask ventilation
Intubation
Fentanyl
Group D
Group F
30 sec
Figure 1. Flow chart showing the time and duration of administration of each drug. Group D = dexmedetomidine–propofol–lidocaine
group; Group F = fentanyl–propofol–lidocaine group.
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Table 1. Demographic characteristics of patients in this
study*
Group D Group F 
p
(n = 30) (n = 30)
Age (yr) 35.77 ± 11.15 32.50 ± 10.75 0.253
Height (cm) 164.33 ± 6.99 167.60 ± 8.76 0.116
Weight (kg) 70.57 ± 12.18 69.37 ± 12.12 0.703
Sex, male/female 11/19 16/14 0.194
*Data presented as n or mean ± standard deviation. Group
D = dexmedetomidine–propofol–lidocaine group; Group F =
fentanyl–propofol–lidocaine group.
assessed in all patients with a three-point scoring 
system (1 = adequate; 2 = difficult but possible; 3 = not
possible). Mask ventilation was maintained for 60
seconds until intubation. For all patients, intubation
was performed by the same anesthesiologist, who had
not been informed of the drug being used. Intubation
was performed using a Macintosh 3 laryngoscope
blade and an 8.0-mm endotracheal tube for males and
a 7.5-mm endotracheal tube for females. After tracheal
intubation, the endotracheal tube cuff (ETTc) was gen-
tly inflated using an analog manometer (Cuff pressure
gauge; VBM Medizintechnik, GmbH, Sulz, Germany)
to between 20–25 cmH2O in all patients. The intuba-
tion conditions were assessed in all patients using a
scoring system that included jaw relaxation (1 = fully
relaxed; 2 = mild resistance; 3 = tight but open; 4 =
impossible), vocal cord position (1 = wide open; 2 =
mid-position; 3 = moving but open; 4 = closed), and
response to intubation and inflation of the ETTc (1 =
none; 2 = diaphragmatic movement; 3 = slight cough;
4 = severe cough) [15]. According to these criteria, in-
tubation conditions were accepted as “excellent” in
patients with a score of 3, “good” in patients with
scores of 4–6, “bad” in those with scores of 7–9, and
“inadequate” in those with scores of 10–12 [15].
Heart rate (HR), systolic arterial pressure (SAP),
mean arterial pressure (MAP) and peripheral oxygen
saturation were recorded for all patients at the fol-
lowing times: before induction, at drug administra-
tion, after propofol administration, at endotracheal
intubation, and 3 and 5 minutes after intubation. The
rate pressure product (RPP) was calculated for each
time-point using the formula RPP = HR × SAP.
If endotracheal intubation could not be success-
fully performed on the first attempt, patients received
0.6 mg/kg rocuronium. Atropine (0.5 mg) could be
administered for bradycardia (HR < 50 beats/min).
Ephedrine (5 mg) was administered if MAP decreased
below 30% of the patient’s baseline control value for
a minimum of 60 seconds. Complications during intu-
bation such as coughing, laryngospasm, bronchospasm
and muscle rigidity were also recorded.
After intubation, anesthesia was maintained in all
patients with 66% nitrous oxide in oxygen and 0.5%
sevoflurane. Patients were ventilated to maintain
end-tidal CO2 values of 35–40 mmHg. Painful surgi-
cal stimuli were avoided during the study.
All data were analyzed using SPSS version 10.0
(SPSS Inc., Chicago, IL, USA). Descriptive statistics for
continuous variables are given as mean ± standard
deviation. Categorical variables are shown as percent-
age. One-way analysis of variance was used to com-
pare HR, blood pressure (MAP and SAP), peripheral
oxygen saturation, age, height, weight, mean intuba-
tion condition score and intubation times. Intra-group
analyses were conducted using t tests with repeated
measurements. The χ2 test was used for sex, side ef-
fects, intubation condition scores and American Soci-
ety of Anesthesiologists physical condition. Pearson’s
correlation coefficients were determined to evaluate
the correlation between intubation condition score and
RPP value after intubation. Values of p < 0.05 were
considered statistically significant.
In a previous report using a combination of fentanyl
and propofol for tracheal intubation without muscle
relaxant, the incidence of poor and inadequate intuba-
tion condition was approximately 37.5% [16]. Based
on these data, and to detect an absolute difference 
of 30% between the proportions of poor and inade-
quate intubating conditions with 80% power and a
0.05 level of significance, 23 patients were required in
each group.
RESULTS
There were no differences between the two groups in
terms of demographic characteristics (Table 1). The
HR was significantly different between the two
groups after the administration of the study drugs
(p < 0.001) and after intubation (p = 0.023), and was
lower in Group D than in Group F. In Group D, the
HR after dexmedetomidine administration and after
propofol administration was significantly lower than
the control values (p < 0.05). In Group F, the HR after
propofol administration and at 3 and 5 minutes after
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intubation was significantly lower than the control
values (p < 0.05) (Figure 2).
MAP after propofol administration and at 3 and 5
minutes after intubation was significantly lower in
Group F than in Group D (p < 0.05). In Group D, the
MAP after propofol and at 5 minutes after intubation
was significantly lower than the control values
(p < 0.05). In Group F, the MAP after propofol admin-
istration and at 3 and 5 minutes after intubation were
significantly lower than the control values (p < 0.05)
(Figure 2).
The RRP values after the administration of the
study drugs (p = 0.019) and after intubation (p = 0.036)
were significantly lower in Group D than in Group F.
In Group D, the RPP values after dexmedetomidine
administration and after propofol administration, at
intubation, and at 3 and 5 minutes after intubation were
significantly lower than the control values (p<0.05). In
Group F, the RPP values after propofol administration
and at 3 and 5 minutes after intubation were signifi-
cantly lower than the control values (p<0.05) (Figure 3).
There were no statistically significant intergroup
or intragroup differences in peripheral oxygen satu-
ration measured at each time-point (p > 0.05).
Six patients in Group D required atropine, versus
none in Group F, which was statistically significant
(p<0.05). None of the patients in either group required
ephedrine.
When mask ventilation conditions before intuba-
tion were assessed, we found that three patients in
Group F had difficulty in mask ventilation, while all
patients in Group D had adequate mask ventilation.
This difference did not reach statistical significance
(p > 0.05) (Table 2).
Scores for jaw relaxation before intubation (p =
0.019), the position of the vocal cords during intuba-
tion (p=0.035), and response to intubation and inflation
of the ETTc (p=0.039) were significantly better in Group
D than in Group F. The overall intubation condition
score based on all criteria was significantly better in
Group D than in Group F (p = 0.010). The mean intu-
bation condition score was also significantly lower in
Group D than in Group F (p = 0.03) (Table 2).
Pearson’s correlation analysis revealed a moderate
positive correlation between the intubation condition
Figure 2. Changes in (A) heart rate and (B) mean arterial pressure after the administration of dexmedetomidine–propofol–lidocaine
(Group D) or fentanyl–propofol–lidocaine (Group F). *p < 0.05 for Group D vs. Group F (one-way analysis of variance); †p < 0.05 for
Group D vs. the control value (t test); ‡p < 0.05 for Group F vs. the control value (t test); After D&F = after dexmedetomidine and fen-
tanyl administration; After propofol = after propofol administration.
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Figure 3. Changes in the rate pressure product after the admin-
istration of dexmedetomidine–propofol–lidocaine (Group D) or  
fentanyl–propofol–lidocaine (Group F). *p < 0.05 for Group D vs.
Group F (one-way analysis of variance); †p < 0.05 for Group D
vs. the control value (t test); ‡p < 0.05 for Group F vs. the control
value (t test); After D&F = after dexmedetomidine and fentanyl
administration; After propofol = after propofol administration.
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score and the RPP value after intubation (p = 0.004,
r = 0.375).
None of the patients in either group required
muscle relaxants for intubation. Furthermore, none
of the patients had laryngospasm or bronchospasm. In
Group F, muscle rigidity rendered mask ventilation
difficult in three patients. However, there was no dif-
ference between the two groups in terms of the devel-
opment of muscle rigidity (p > 0.05).
DISCUSSION
Dexmedetomidine is a highly selective α2 adreno-
ceptor agonist with analgesic and sedative effects
[7,8,12,14,17,18]. In this study, the administration of
dexmedetomidine in combination with propofol and
lidocaine provided better intubation conditions than
with fentanyl. Propofol and lidocaine in combina-
tion with either dexmedetomidine or fentanyl blunt
intubation-induced hemodynamic responses; however,
MAP and RPP are more stable with dexmedetomidine
than with fentanyl. We demonstrated that the combi-
nation of dexmedetomidine, propofol and lidocaine
is more suitable than the combination of fentanyl, pro-
pofol and lidocaine for tracheal intubation without
using muscle relaxants.
Dexmedetomidine was reported to blunt hemo-
dynamic responses during laryngoscopy, intubation
and extubation [19–22]. Snapir et al [23] reported that
dexmedetomidine reduced myocardial perfusion, myo-
cardial oxygen demand and the RPP. In this study, dex-
medetomidine significantly reduced the RPP compared
with the control value. In addition, the blunting effect
on RPP responses during laryngoscopy was significan-
tly better with dexmedetomidine than with fentanyl.
Üzümcügil et al [9] compared dexmedetomidine-
propofol and fentanyl-propofol combinations during
laryngeal mask placement and concluded that dex-
medetomidine is as successful as fentanyl in terms of
mask placement conditions. Similarly, we found that
intubation without muscle relaxants can be better
achieved when dexmedetomidine, rather than fentanyl,
is combined with a propofol–lidocaine regimen.
Table 2. Intubation condition scores of patients*
Group D (n = 30) Group F (n = 30) p
Mask ventilation 0.237
Easy 30 (100) 27 (90.0) 
Difficult 0 3 (10.0)
Jaw relaxation 0.019
Fully relaxed  29 (96.7) 21 (70.0)
Mild resistance 1 (3.3) 5 (16.7)
Tight but open 0 4 (13.3)
Vocal cord position 0.035
Wide open 20 (66.7) 12 (40.0)
Mid-position 9 (30.0) 11 (36.7)
Moving but open 1 (3.3) 7 (23.3)
Response to intubation and ETTc 0.039
None 17 (56.7) 10 (33.3)
Diaphragmatic movement 4 (13.3) 4 (13.3)
Slight cough 7 (23.3) 5 (16.7)
Severe cough 2 (6.7) 11 (36.7)
Intubation condition score 0.010
Excellent 17 (56.7) 9 (30.0)
Good 11 (36.7) 8 (26.7)
Poor 2 (6.7) 9 (30.0)
Inadequate 0 4 (13.3)
Mean intubation condition score 4.20 ± 1.21 5.88 ± 2.44 0.030
*Data presented as n (%) or mean ± standard deviation. Group D = Dexmedetomidine–propofol–lidocaine group; Group F =
fentanyl–propofol–lidocaine group; ETTc = endotracheal tube cuff.
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Üzümcügil et al [9] also reported greater MAP
decreases with fentanyl than with dexmedetomidine,
although there was no significant difference between
the two groups. It was reported that, after a dose of
2.0–2.5 mg/kg propofol, the mean blood pressure
may decrease by 25–40% due to its vasodilatory and
myocardial depressing effects [24]. Following a bolus
dose of dexmedetomidine, an increase in blood pres-
sure of 22% and a decrease in HR of 27% may occur
due to its effects on peripheral α2 adrenoceptors [24].
We observed a smaller decrease in MAP in Group D,
as compared with control values, than in Group F. We
think that this is due to the effects of dexmedetomi-
dine on peripheral α2 adrenoceptors. Although the
decrease in MAP in Group F was well tolerated in
these pre-hydrated, healthy young subjects, we
believe this may constitute a risk for elderly, hypov-
olemic and debilitated patients.
Üzümcügil et al [9] used fentanyl and dexmedeto-
midine in their similar study and reported that both
drugs reduce HR. However, the decrease was not
clinically significant. In our study, the mean HR was
lower in Group D than in Group F, necessitating an in-
creased use of atropine in Group D. We believe that this
decrease in HR constitutes a risk for elderly patients
and therefore warrants attention.
Previous studies have demonstrated that a single
0.5μg/kg dose of dexmedetomidine before extubation
in pediatric patients blunted the airway reflexes and
hemodynamic responses to extubation [25,26]. Simi-
larly, in our study, diaphragmatic movements and
coughing in response to intubation and inflation of the
ETTc were significantly lower in Group D than in
Group F. In vitro studies conducted on the bronchial tis-
sue of human and animal subjects showed that α2
adrenoceptor stimulation can attenuate and prevent
bronchoconstriction [27,28]. In an experimental study,
0.5 μg/kg of intravenous dexmedetomidine inhibited
bronchoconstriction caused by histamine in dogs
anesthetized with thiopental [29]. The authors of that
study concluded that dexmedetomidine may be very
useful in patients with high airway reactivity [29]. We
think that dexmedetomidine can attenuate bronchial
reactivity and airway reflexes, such as coughing, which
can be an advantage in tracheal intubation without
using muscle relaxants.
To prevent hypertension, tachycardia and the de-
velopment of the coughing reflex in response to laryn-
goscopy, we administered 1.5 mg/kg lidocaine to all
patients before propofol administration [15,16]. Pre-
vious studies support the synergistic effect of lido-
caine in combination with propofol [16,30]. Therefore,
the synergistic effects of the lidocaine–propofol–
dexmedetomidine combination may be among the
factors responsible for the highly favorable intuba-
tion conditions in this study.
Muscle rigidity is a common side effect of opioids
after rapid injection and may interfere with mask
ventilation [15]. In our study, although muscle rigidity
occurred in three patients in Group F, it was not
observed in Group D.
We did not need to include a control group given
with propofol alone because increasing the conven-
tional induction dose of propofol might elicit adverse
hemodynamic effects.
In conclusion, our study has shown that in adult
patients with normal airways 1 μg/kg dexmedet-
omidine before propofol and lidocaine induction
provides better intubation conditions without muscle
relaxants than 2 μg/kg fentanyl. Therefore, dexme-
detomidine may offer an alternative to opioids in
combination with propofol for intubation without
muscle relaxants. However, side effects such as bra-
dycardia should be considered when administering
dexmedetomidine.
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